Adding Winrevair treatment significantly reduced the risk of clinical worsening in people with a recent PAH diagnosis, per a ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ADVANCE OUTCOMES study evaluating the use of an extended-release ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

Phase 3 study results evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension were announced.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Pulmonary hypertension is classified by the World Health Organization according to its causes or associated underlying conditions: Group 1: Pulmonary arterial hypertension (PAH) refers to increased ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

United Therapeutics’ first quarter results came in above Wall Street’s expectations, but the market reacted negatively, with ...